

Prof. Ahmet BİLİCİ

Personal Information

Email: abilici@medipol.edu.tr

Web: <https://avesis.medipol.edu.tr/abilici>

Education Information

Expertise In Medicine, İstanbul University-Cerrahpaşa, Cerrahpaşa Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Turkey 2014 - 2018

Post Doctorate of Medicine, Diğer (Kurumlar,hastaneler Vb.), Hastaneler, İstanbul Kartal Dr.Lütfi Kırdar Eğitim Ve Araştırma Hastanesi, Turkey 2008 - 2011

Undergraduate, İstanbul University-Cerrahpaşa, Cerrahpaşa Tıp Fakültesi, Turkey 1991 - 1998

Academic Titles / Tasks

Professor, İstanbul Medipol University, Tıp Fakültesi, 2018 - Continues

Associate Professor, İstanbul Medipol University, Tıp Fakültesi, 2013 - 2018

Associate Professor, Diğer (Kurumlar,hastaneler Vb.), Hastaneler, İstanbul Şişli Etfal Eğitim Ve Araştırma Hastanesi, 2012 - 2013

Expert, Diğer (Kurumlar,hastaneler Vb.), Hastaneler, İstanbul Şişli Etfal Eğitim Ve Araştırma Hastanesi, 2011 - 2012

Research Assistant, Diğer (Kurumlar,hastaneler Vb.), Hastaneler, İstanbul Kartal Dr.Lütfi Kırdar Eğitim Ve Araştırma Hastanesi, 2008 - 2011

Lecturer, Kocaeli University, Tıp Fakültesi, 2007 - 2008

Research Assistant, İstanbul University-Cerrahpaşa, Cerrahpaşa Tıp Fakültesi, 1998 - 2004

Advising Theses

Ahmet B., Epitelyal over kanserli hastalarda sistemik inflamatuvar indeks parametrelerinin platin direnci üzerine, nöks özelliklerine ve sağkalımlara etkisi, Expertise In Medicine, C.İDRİSOĞLU(Student), 2022

Ahmet B., Lokal ileri meme kanserli hastalarda neoadjuvan kemoterapi sonrası tümör-infiltrate eden lenfosit (TIL) ve androjen reseptör (AR) ekspresyonlarındaki değişim ve rezidü tümör varlığı arasındaki ilişki, Expertise In Medicine, V.BUĞRA(Student), 2021

Ahmet B., Neoadjuvan kemoterapi alan lokal ileri meme kanserli hastalarda moleküler alt tiplere göre yanıt oranları ile klinik sonuçlar üzerine etkili prediktif ve prognostik faktörlerin gözden geçirilmesi, Expertise In Medicine, A.YILDIZ(Student), 2019

Ahmet B., İstanbul Medipol Üniversitesi Hastanesi'nde metastatik kolorektal kanserli hastalarda klinikopatolojik faktörler ve prognoz üzerine etkileri, Expertise In Medicine, B.ÇAKAN(Student), 2018

Ahmet B., Opere mide kanserli hastalarda ADAM-17 ekspresyonunun klinikopatolojik faktörler ve sağkalımla ilişkisi, Post Doctorate of Medicine, D.AYDIN(Student), 2014

Published journal articles indexed by SCI, SSCI, and AHCI

1. IMpassion132 double-blind randomised phase III trial of chemotherapy with or without

atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer

Dent R, André F, Gonçalves A, Martin M, Schmid P, Schütz F, Kümmel S, Swain S, BİLİCİ A, Loirat D, et al. *Annals of Oncology*, vol.35, no.7, pp.630-642, 2024 (SCI-Expanded)

- II. **Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study**
KUTLU Y, Dae S. A., YILMAZ F., Erdem D., Sendur M. A. N., Akbas S., Senocak Tasci E., Bas O., Dane F., SAKİN A., et al. *Cancers*, vol.16, no.12, 2024 (SCI-Expanded)
- III. **Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer**
KUTLU Y., Cekin R., AYDIN S., Shbair A. T. M., BİLİCİ A., Arici S., Oven B. B., AÇIKGÖZ Ö., Ozcan E., ÖLMEZ Ö. F., et al. *Current Problems in Cancer*, vol.50, 2024 (SCI-Expanded)
- IV. **Beyond traditional therapies: clinical significance of complex molecular profiling in patients with advanced solid tumours-results from a Turkish multi-centre study**
ÖLMEZ Ö. F., BİLİCİ A., ER Ö., BİŞGİN A., Sevinc A., Akman T., Uslu R., Mandel N. M., YALÇIN Ş., Teomete M., et al. *Japanese journal of clinical oncology*, vol.54, no.5, pp.562-568, 2024 (SCI-Expanded)
- V. **The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing**
KÖSTEK O., Demirel A., Hacıoğlu M. B., TAŞTEKİN D., KARABULUT S., Gündoğdu A., Sever N., Ayhan M., Çelebi A., Majidova N., et al. *Journal of Chemotherapy*, 2024 (SCI-Expanded)
- VI. **Integrated FDG-PET/CT contribution over cross-sectional imaging in recurrence or progression of pancreaticobiliary neoplasms**
Karaalioglu B., ÇAKIR T., KUTLU Y., ŞEKER M., BİLİCİ A. *Abdominal Radiology*, vol.49, no.1, pp.131-140, 2024 (SCI-Expanded)
- VII. **The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study**
Güven D. C., Aykan M. B., MUĞLU H., BAYRAM E., Helvacı K., DURSUN B., Celayir M., Chelebiyev E., Nayir E., ERMAN M., et al. *Cancer Medicine*, vol.13, no.1, 2024 (SCI-Expanded)
- VIII. **Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide**
Goktas Aydin S., Kutlu Y., Muglu H., Aydin A., Acikgoz Ö., Hamdard J., Karci E., Bilici A., Olmez Ö. F., Yildiz Ö. *CANCER CHEMOTHERAPY AND PHARMACOLOGY*, vol.93, pp.71-78, 2024 (SCI-Expanded)
- IX. **Characteristic features and prognostic factors in gastric cancer patients with bone metastases: multicenter experience**
HAMDARD J., BİLİCİ A., Sakin A., Kahraman S., Yasin A. I., Kalaci E., Gokmen I., AÇIKGÖZ Ö., KUTLU Y., Sendur M. A. N., et al. *Journal of Chemotherapy*, 2024 (SCI-Expanded)
- X. **Prognostic implications of response to neoadjuvant chemotherapy in breast cancer subtypes**
Yıldiz A., BİLİCİ A., AÇIKGÖZ Ö., HAMDARD J., BASIM P., ÇAKIR T., ÇAKIR A., ÖLMEZ Ö. F., Gezen C., YILDIZ Ö. *Journal of Chemotherapy*, 2024 (SCI-Expanded)
- XI. **Genetic testing and counseling challenges in personalized breast cancer care: review article with insights from Türkiye.**
Cicin I., Karadurmus N., Bilici A., Bahsi T., Sendur M. A., Demirci U., Goksu S. S., Er O., Bisgin A., Ozturk Saglam O. F., et al. *Future oncology (London, England)*, 2023 (SCI-Expanded)
- XII. **Impact of SPARC expression on treatment response of pembrolizumab and brain metastasis in patients with metastatic non-small cell lung cancer**
GÖKTAŞ AYDIN S., BİLİCİ A., ÇALIŞ E., KUTLU Y., HAMDARD J., MUĞLU H., Fatih Olmez Ö. F., KARCI E., AÇIKGÖZ Ö.

INTERNATIONAL IMMUNOPHARMACOLOGY, vol.124, 2023 (SCI-Expanded)

- XIII. **Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study**
Bilici A, Koca S, Karaagac M, Aydin S. G., Eraslan E., Kaplan M. A., Ocak B., Sezgin Göksu S., Paydaş S., Akgul F., et al.
Journal of Cancer Research and Clinical Oncology, vol.149, no.11, pp.8243-8253, 2023 (SCI-Expanded)
- XIV. **The Prognostic Utility of the Metastatic Lymph Node Ratio and the Number of Regional Lymph Nodes Removed from Patients with Small Bowel Adenocarcinomas**
Aydin D., KEFELİ U., Ozcelik M., Erdem G. U., ŞENDUR M. A. N., Yildirim M. E., Oven B. B., BİLİCİ A., Gumus M.
Medicina (Lithuania), vol.59, no.8, 2023 (SCI-Expanded)
- XV. **Clinicopathological and Survival Characteristics of Mismatch Repair Status and PD-1 Expression in Serous Ovarian Cancer**
Olmez F., Oglak S. C., Akgol S., ÖLMEZ Ö. F., BİLİCİ A., Akbayir O., Ozkose Z. G., Can E., Unal O., Sirinoglu H. A.
Journal of the College of Physicians and Surgeons Pakistan, vol.33, no.6, pp.66-672, 2023 (SCI-Expanded)
- XVI. **Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy**
Kutlu Y., Aydin S. G., Bilici A., Oven B. B., Ölmez Ö. F., Açıkgoz Ö., Hamdard J.
Medicine (United States), vol.102, no.15, 2023 (SCI-Expanded)
- XVII. **Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study**
BİLİCİ A., ÖLMEZ Ö. F., Kaplan M. A., Oksuzoglu B., Sezer A., Karadurmus N., ÇUBUKÇU E., Sendur M. A. N., AKSOY S., Erdem D., et al.
ACTA ONCOLOGICA, vol.62, no.4, pp.381-390, 2023 (SCI-Expanded)
- XVIII. **The Predictive Importance of Body Mass Index on Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer**
Emirzeoglu L., Arici S., Sahin A. B., Ocak B., AK N., Ay S., MAMMADOV E., Turna H., BİLİCİ A.
Breast Care, vol.18, no.1, pp.42-48, 2023 (SCI-Expanded)
- XIX. **Survival outcomes of patients with oligometastatic non-small cell lung cancer who were treated with radical therapy: a multicenter analysis**
Acikgoz O., Bilici A., Tataroglu Ozyukseler D., Göktaş Aydın S., Selcukbiricik F., Rzaade R., Ölmez Ö. F., Caglar H. B.
Turkish Journal of Medical Sciences, vol.53, no.4, pp.949-961, 2023 (SCI-Expanded)
- XX. **Relationship between the change in tumour-infiltrating lymphocyte level and residual tumour after neoadjuvant chemotherapy in patients with locally advanced breast cancer**
Erol V. B., GÖKTAŞ AYDIN S., BİLİCİ A., ÇAKIR A., AÇIKGÖZ Ö., ÖLMEZ Ö. F., BASIM P.
Journal of Chemotherapy, vol.35, no.7, pp.662-670, 2023 (SCI-Expanded)
- XXI. **Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group**
Gürbüz M., Kiliçkap S., BİLİCİ A., Karadurmuş N., Sezer A., ŞENDUR M. A. N., PAYDAŞ S., Artaç M., Fulden Yumuk P., Gürsoy P., et al.
Medicine (United States), vol.101, no.50, 2022 (SCI-Expanded)
- XXII. **Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group**
Gürbüz M., KUTLU Y., Akkuş E., KÖKSOY E. B., Köse N., Öven B. B., Uluç B. O., Demiray A. G., Erdem D., Demir B., et al.
Journal of Cancer Research and Clinical Oncology, vol.148, no.12, pp.3547-3555, 2022 (SCI-Expanded)
- XXIII. **Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group**
Erol C., ŞENDUR M. A. N., Bilgetekin I., Garbioglu D. B., HAMDARD J., Akbas S., Hizal M., Arslan C., Sevinc A., Kucukarda A., et al.
Journal of Cancer Research and Therapeutics, vol.18, no.9, pp.347-353, 2022 (SCI-Expanded)
- XXIV. **Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer.**

GÖKTAŞ AYDIN S., Cakan Demirel B., BİLİCİ A., Topcu A., Aykan M. B., KAHRAMAN S., AKBIYIK I., Atci M. M., ÖLMEZ Ö. F., Yaren A., et al.

Current medical research and opinion, vol.38, no.10, pp.1751-1758, 2022 (SCI-Expanded)

- XXV. **The Role of 18F-FDG PET/CT in Predicting the Neoadjuvant Treatment Response in Patients with Locally Advanced Breast Cancer**
Aydin S. G., BİLİCİ A., ÖLMEZ Ö. F., OVEN B. B., AÇIKGÖZ Ö., ÇAKIR T., BASIM P., ÇAKIR A., KUTLU Y., HAMDARD J.
Breast Care, vol.17, no.5, pp.470-479, 2022 (SCI-Expanded)
- XXVI. **The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study**
Hizal M., Bilgin B., Paksoy N., AÇIKGÖZ Ö., Sezer A., Gürbüz M., Ak N., Yücel Ş., Ayhan M., Erol C., et al.
Journal of Cancer Research and Clinical Oncology, vol.148, no.6, pp.1501-1508, 2022 (SCI-Expanded)
- XXVII. **Efficacy and safety profile of COVID-19 vaccine in cancer patients: A prospective, multicenter cohort study**
Yasin A. I., Aydin S. G., SÜMBÜL B., KORAL L., ŞİMŞEK M., Geredeli Ç., Öztürk A., Perkin P., Demirtaş D., Erdemoglu E., et al.
Future Oncology, vol.18, no.10, pp.1235-1244, 2022 (SCI-Expanded)
- XXVIII. **Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study**
BİLİCİ A., Uysal M., Menekse S., Akin S., Yildiz F., Turan M., SEZGİN GÖKSU S., Beypinar I., Sakalar T., Değirmenci M., et al.
Cancer Investigation, vol.40, no.2, pp.199-209, 2022 (SCI-Expanded)
- XXIX. **Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer**
İLHAN Y., TATLI A. M., Teker F., Onder A. H., Kose F., Geredeli C., Karaagac M., Kaplan M. A., İNANÇ M., GÖKTAŞ AYDIN S., et al.
International Journal of Gynecological Cancer, vol.32, 2022 (SCI-Expanded)
- XXX. **Platelet to lymphocyte ratio is associated with tumor localization and outcomes in metastatic colorectal cancer**
AÇIKGÖZ Ö., Cakan B., Demir T., BİLİCİ A., OVEN B. B., HAMDARD J., OLMUŞÇELİK O., ÖLMEZ Ö. F., ŞEKER M., YILDIZ Ö.
Medicine (United States), vol.100, no.44, 2021 (SCI-Expanded)
- XXXI. **Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck**
SEZGİN GÖKSU S., TATLI A. M., Geredeli Ç., Atci M., Besen A. A., Mertsoylu H., Uysal M., Özdoğan M., Aydın S. G., BİLİCİ A., et al.
Cancer Chemotherapy and Pharmacology, vol.88, no.5, pp.805-812, 2021 (SCI-Expanded)
- XXXII. **Comparison of response and survival of first-line crizotinib therapy according to EML-4 ALK fusion variants in advanced non-small cell lung cancer patients: A Turkish Oncology Group study**
TATLI A. M., Yumuk P. F., Oz B., BİLİCİ A., GURSOY P., GOKER E., SEZER A., ÖZET A., DEMİRCİ U., BOZKURLAR E., et al.
Journal of B.U.ON., vol.26, no.6, pp.2457-2464, 2021 (SCI-Expanded)
- XXXIII. **Merkel cell carcinoma in Turkey: A multicentric study**
Yildiz F., Demirci U., Kucukarda A., BÜYÜKŞİMŞEK M., Sakalar T., Topcu T., Aslan F., Tufan G., AYDIN ÜLGEN Ö., Turna H., et al.
Journal of Cancer Research and Therapeutics, vol.17, no.6, pp.1525-1529, 2021 (SCI-Expanded)
- XXXIV. **The Effect of Primary Surgery in Patients with De Novo Stage IV Breast Cancer with Bone Metastasis Only (Protocol BOMET MF 14-01): A Multi-Center, Prospective Registry Study**
Soran A., Dogan L., Isik A., Ozbas S., Trabulus D. C., Demirci U., KARANLIK H., Soyder A., Dag A., BİLİCİ A., et al.
Annals of Surgical Oncology, vol.28, no.9, pp.5048-5057, 2021 (SCI-Expanded)
- XXXV. **Prognostic significance of primary tumor localization in patients with metastatic colorectal cancer: Is it beneficial to select targeted treatment? Real-life experience from Turkey**

Cakan B., AÇIKGÖZ Ö., BİLİCİ A., Demir T., Oven B. B., HAMDARD J., OLMUŞÇELİK O., ÖLMEZ Ö. F., ŞEKER M., YILDIZ Ö.

Journal of B.U.ON., vol.26, no.5, pp.1908-1917, 2021 (SCI-Expanded)

XXXVI. Triple-negative breast cancer presented with metastasis to the heart as first sign of recurrence

BAYRAMGİL A., BİLİCİ A., HAMDARD J., AÇIKGÖZ Ö., ŞEKER M., KILIÇASLAN F., KÖKSAL C., Buyukpinarbasili N., MAMMADOV E., GÖKTAŞ AYDIN S., et al.

Breast Journal, vol.27, no.1, pp.56-57, 2021 (SCI-Expanded)

XXXVII. The conversion of RAS status in metastatic colorectal cancer patients after first-line biological agent treatment

Arici S., HAMDARD J., Sakin A., Sengiz Erhan S., Atci M. M., Cekin R., Saka B., Köse E., Saydam T., Geredeli C., et al. Colorectal Disease, vol.23, no.1, pp.206-212, 2021 (SCI-Expanded)

XXXVIII. Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey

Hacioglu M. B., Kostek O., KARABULUT S., TAŞTEKİN D., SEZGİN GÖKSU S., Alandag C., Akagunduz B., Bilgetekin I., CANER B., Sahin A. B., et al.

Journal of B.U.ON., vol.25, no.4, pp.1897-1903, 2020 (SCI-Expanded)

XXXIX. Elevation in serum uric acid levels predicts favourable response to erlotinib treatment in patients with metastatic non-small-cell lung cancer

Selcukbiricik F., Ozdogan E., Dagek T., Tanju S., Erus S., Ertuglu L. A., Kapdağlı M., Tural D., BİLİCİ A., Dilege S., et al. Journal of Clinical Pharmacy and Therapeutics, vol.45, no.2, pp.303-308, 2020 (SCI-Expanded)

XL. Does primary tumor localization has prognostic importance in seminoma patients?: Turkish oncology Group study

Yildiz B., Kucukarda A., Gokyer A., Demiray A. G., PAYDAŞ S., Aral I. P., Gumusay O., BİLİCİ A., Akdeniz N., Bahceci A., et al.

Journal of B.U.ON., vol.25, no.2, pp.1130-1135, 2020 (SCI-Expanded)

XLI. The potential prognostic role of peritumoral eosinophils within whole tumor-associated inflammatory cells and stromal histological characteristics in colorectal cancer

Ramadan S., Saka B., Yarikkaya E., BİLİCİ A., ÖNCEL M.

Polish Journal of Pathology, vol.71, no.3, pp.207-220, 2020 (SCI-Expanded)

XLII. Anti-Ri-associated paraneoplastic neurological syndrome: Initial symptom of breast cancer with HER2 overexpression and treatment by dual HER2 blockade

ÖLMEZ Ö. F., Kinikoglu O., Yilmaz N. H., BİLİCİ A., ÇUBUKÇU E., ŞEKER M., ÇAKIR T., YILDIZ Ö., HAMDARD J.

Journal of Oncology Pharmacy Practice, vol.25, no.6, pp.1526-1530, 2019 (SCI-Expanded)

XLIII. Prognostic Significance of Metastatic Lymph Node Ratio in Patients with pN3 Gastric Cancer Who Underwent Curative Gastrectomy

BİLİCİ A., Selcukbiricik F., ŞEKER M., Oven B. B., ÖLMEZ Ö. F., YILDIZ Ö., OLMUŞÇELİK O., HAMDARD J., AÇIKGÖZ Ö., ÇAKIR A., et al.

Oncology Research and Treatment, vol.42, no.4, pp.204-211, 2019 (SCI-Expanded)

XLIV. The relationship between positron emission tomography-computed tomography imaging and histopathological features of thyroid incidentalomas detected during follow-up for primary malignancy

Oven B., Kilicoglu Z., BİLİCİ A., Tatoglu M., Canberk S., Tilki M., Vardar F.

Journal of Cancer Research and Therapeutics, vol.15, no.3, pp.589-595, 2019 (SCI-Expanded)

XLV. Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes

Esin E., Oksuzoglu B., BİLİCİ A., ÇİÇİN İ., Kostek O., Kaplan M., AKSOY S., AKTAŞ B. E., Ozdemir O., Alacacioglu A., et al. Cancer Chemotherapy and Pharmacology, vol.83, no.1, pp.131-143, 2019 (SCI-Expanded)

XLVI. Comparison of skeletal muscle mass loss in patients with metastatic colorectal cancer treated with regorafenib or TAS-102

Hacioglu M. B., Kostek O., Kurt N., Kucukarda A., Gokyer A., Ustabasioglu F. E., Karatas F., TUNÇBİLEK N., UZUNOĞLU S., BİLİCİ A., et al.

Journal of B.U.ON., vol.24, no.5, pp.2198-2204, 2019 (SCI-Expanded)

- XLVII. **Role of urotensin-2 in 5-fluorouracil-related arterial vasoconstriction in cancer patients**
ŞEKER M., Isen H. C., Çevirme N., Aydın S., BİLİCİ A., Bulut H., Yasin A. I., Coban E., Demir T., Aliyev A., et al.
Oncology Research and Treatment, vol.41, no.9, pp.545-549, 2018 (SCI-Expanded)
- XLVIII. **Capecitabine-cisplatin versus 5-fluorouracil/leucovorin in combination with radiotherapy for adjuvant therapy of lymph node positive locally advanced gastric cancer**
Ustaalioglu B. B. O., BİLİCİ A., Tilki M., Surmelioglu A., Erkol B., Figen M., Uyar S.
Journal of Cancer Research and Therapeutics, vol.14, no.10, 2018 (SCI-Expanded)
- XLIX. **Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy**
YILDIZ İ., BİLİCİ A., Karadurmuş N., OZER L., Tural D., Kaplan M. A., Akman T., Bayoglu I. V., Uysal M., Yildiz Y., et al.
Tumori, vol.104, no.6, pp.444-450, 2018 (SCI-Expanded)
- L. **Evaluation of Prognostic Factors and Adjuvant Chemotherapy in Patients With Small Bowel Adenocarcinoma Who Underwent Curative Resection**
Aydin D., Sendur M. A., KEFELİ U., Unal O. U., Tastekin D., Akyol M., Tanrikulu E., Ciltas A., Ustaalioglu B. B., Uysal M., et al.
Clinical Colorectal Cancer, vol.16, no.3, pp.220-227, 2017 (SCI-Expanded)
- LI. **Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors**
Gumus M., BİLİCİ A., Odabas H., Ustaalioglu B. B. O., Kandemir N., Demirci U., Cihan S., Bayoglu I. V., Ozturk T., Turkmen E., et al.
World Journal of Urology, vol.35, no.7, pp.1103-1110, 2017 (SCI-Expanded)
- LII. **Is Change in Hemoglobin Level a Predictive Biomarker of Tyrosine Kinase Efficacy in Metastatic Renal Cell Carcinoma? A Turkish Oncology Group Study**
Bilir C., YILDIZ İ., BİLİCİ A., Ucar M., Berk V., Yıldız Y., Yazıcı O., İmamoğlu G. İ., Karadurmuş N., Pilancı K. N., et al.
Cancer Investigation, vol.35, no.4, pp.248-255, 2017 (SCI-Expanded)
- LIII. **Correlation of Caveolin-1 Expression with Prognosis in Patients with Gastric Cancer after Gastrectomy**
ŞEKER M., Aydın D., BİLİCİ A., Yavuzer D., Ozgun M. G., Ozcelik M., Aydın O., ALİUSTAOĞLU M.
Oncology Research and Treatment, vol.40, no.4, pp.185-190, 2017 (SCI-Expanded)
- LIV. **Serum uric acid as a surrogate marker of favorable response to bevacizumab treatment in patients with metastatic colon cancer**
Selcukbiricik F., Kanbay M., Solak Y., BİLİCİ A., Kanitez M., Balık E., Mandel N.
Clinical and Translational Oncology, vol.18, no.11, pp.1082-1087, 2016 (SCI-Expanded)
- LV. **Evaluation of prognostic factors and treatment in advanced small bowel adenocarcinoma: Report of a multi-institutional experience of Anatolian Society of Medical Oncology (ASMO)**
Aydin D., Sendur M. A., KEFELİ U., Unal O. U., Tastekin D., Akyol M., Tanrikulu E., Ciltas A., Ustaalioglu B. B., Dede D. S., et al.
Journal of B.U.ON., vol.21, no.5, pp.1242-1249, 2016 (SCI-Expanded)
- LVI. **Prognostic importance of RASSF2 expression in patients with gastric cancer who had undergone radical gastrectomy**
Aydin D., BİLİCİ A., Kayahan S., Yavuzer D., Basar M., ALİUSTAOĞLU M.
Clinical and Translational Oncology, vol.18, no.6, pp.608-616, 2016 (SCI-Expanded)
- LVII. **Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases**
Ulas A., BİLİCİ A., Durnali A., Tokluoglu S., Akinci S., SILAY K., Oksuzoglu B., Alkis N.
Tumor Biology, vol.37, no.1, pp.1131-1140, 2016 (SCI-Expanded)
- LVIII. **The differences of clinicopathological factors for breast cancer in respect to time of recurrence and effect on recurrence-free survival**
Oven Ustaalioglu B., Balvan O., BİLİCİ A., Develi A., ALİUSTAOĞLU M., Vardar F., Erkol B.
Clinical and Translational Oncology, vol.17, no.11, pp.895-902, 2015 (SCI-Expanded)

- LIX. **Treatment preferences in stage IA and IB testicular seminoma: multicenter study of Anatolian Society of Medical Oncology**
BİLİCİ A., Ozturk T., Turkmen E., Odabas H., Cihan S., Selcukbiricik F., ERDOĞAN B., Urakci Z., Kandemir N., Bayoglu I. V., et al.
World Journal of Urology, vol.33, no.10, pp.1613-1622, 2015 (SCI-Expanded)
- LX. **Prognostic markers for metastatic colon cancer patients undergoing multiple metastasectomies**
Üstaalioglu B. B. O., Tilki M., Kılıçoğlu Z. G., BİLİCİ A., Sürmelioğlu A., Ustaalioglu R., Erkol B.
Turkish Journal of Gastroenterology, vol.26, no.5, pp.386-391, 2015 (SCI-Expanded)
- LXI. **Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy**
Aydin D., BİLİCİ A., Yavuzer D., KEFELİ U., Tan A., Ercelep O., Mert A., Yuksel S., Ozcelik M., Isik D., et al.
Clinical and Translational Oncology, vol.17, no.8, pp.604-611, 2015 (SCI-Expanded)
- LXII. **Prognostic significance of the recurrence pattern and risk factors for recurrence in patients with proximal gastric cancer who underwent curative gastrectomy**
BİLİCİ A., Selcukbiricik F.
Tumor Biology, vol.36, no.8, pp.6191-6199, 2015 (SCI-Expanded)
- LXIII. **The changing of serum vitamin B12 and homocysteine levels after gastrectomy in patients with gastric cancer: do they associate with clinicopathological factors?**
BİLİCİ A., Sonkaya A., Ercan S., Ustaalioglu B. B. O., Seker M., ALIUSTAOĞLU M., Orcun A., Gumus M.
Tumor Biology, vol.36, no.2, pp.823-828, 2015 (SCI-Expanded)
- LXIV. **Clinical importance of discordance of hormone receptors and HER2/neu status after neoadjuvant chemotherapy in breast cancer**
Ustaalioglu B. B. O., Vardar F. A., BİLİCİ A., Gurleyik G., Erkol B., Kefeli U., ALIUSTAOĞLU M.
Journal of B.U.ON., vol.19, no.4, pp.879-886, 2014 (SCI-Expanded)
- LXV. **Prognostic factors related with survival in patients with pancreatic adenocarcinoma**
BİLİCİ A.
World Journal of Gastroenterology, vol.20, no.31, pp.10802-10812, 2014 (SCI-Expanded)
- LXVI. **Important factors affecting adjuvant treatment decision in stage IA breast cancer patients in Turkey**
Oven Ustaalioglu B. B., BİLİCİ A., Yilmaz B. E., ALIUSTAOĞLU M., Seker M., Vardar F., Gumus M.
Breast Care, vol.9, no.2, pp.123-127, 2014 (SCI-Expanded)
- LXVII. **Prognostic significance of protein kinase B/Akt pathway in patients with non-small cell lung cancer**
Mayadagli A., Gul S. K., BİLİCİ A., Oruc A. F., Kocak M., Ozkan A., Aksu A., Barisik N. O., Gumus M.
Journal of B.U.ON., vol.19, no.1, pp.157-163, 2014 (SCI-Expanded)
- LXVIII. **Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2- negative advanced gastric cancer**
BİLİCİ A., Selcukbiricik F., Demir N., Ustaalioglu B. B. O., Dikilitas M., YILDIZ Ö.
Asian Pacific Journal of Cancer Prevention, vol.15, no.20, pp.8661-8666, 2014 (SCI-Expanded)
- LXIX. **Prognostic factors for lymph node negative stage I and IIA non-small cell lung cancer: Multicenter experiences**
Ustaalioglu B. B. O., Unal O. U., Turan N., BİLİCİ A., Kaya S., Eren T., Ulas A., Inal A., Berk V., Demirci U., et al.
Asian Pacific Journal of Cancer Prevention, vol.14, no.11, pp.6287-6292, 2013 (SCI-Expanded)
- LXX. **Clinical and pathologic features of patients with rare ovarian tumors: Multi-center review of 167 patients by the anatolian society of medical oncology**
BİLİCİ A., İNANÇ M., Ulas A., Akman T., Seker M., Babacan N. A., Inal A., Bal O., Koral L., Sevinc A., et al.
Asian Pacific Journal of Cancer Prevention, vol.14, no.11, pp.6493-6499, 2013 (SCI-Expanded)

Articles Published in Other Journals

- I. **The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data**

AYDIN S., ÖLMEZ Ö. F., Selvi O., Geredeli C., ÖZDEN F., BİLİCİ A., AÇIKGÖZ Ö., KARCI E., KUTLU Y., HAMDARD J., et al.
Journal of Gastrointestinal Cancer, vol.55, no.1, pp.227-236, 2024 (ESCI)

- II. **THE IMPORTANCE OF CLINICAL AND LABORATORY PARAMETERS OF BONE MARROW METASTASIS IN PATIENTS WITH SOLID MALIGNANCY-SINGLE CENTER EXPERIENCE**
Sadri S., J., Beköz H. S., Cakir A., ÖLMEZ Ö. F., Bilici A.
Karya Journal of Health Science, vol.4, no.3, pp.187-191, 2023 (Peer-Reviewed Journal)
- III. **Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study**
Aydın S. G., Kavak E. E., Topcu A., Bayramgil A., Akgul F., Kahraman S., Aykan M. B., Altıntaş Y. E., Helvacı K., Ürün Y., et al.
Biomolecules and Biomedicine, vol.23, no.6, pp.1089-1095, 2023 (Scopus)
- IV. **Impact of systemic inflammatory markers in patients with ALK-positive non-small cell lung cancer treated with crizotinib**
ÖLMEZ Ö. F., BİLİCİ A., GURSOY P., ÇUBUKÇU E., SAKIN A., KORKMAZ T., CİL İ., ÇAKAR B., MENEKSE S., DEMİR T., et al.
Pulmonology, vol.29, no.6, pp.478-485, 2023 (Scopus)
- V. **The Efficacy And Safety of CDK 4/6 Inhibitors Plus Endocrine Therapy With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2- Negative Metastatic Breast Cancer Patients**
açikgöz o., Göktaş Aydın S., Bilici A., Kutlu Y., Muğlu H., Karcı E., J., Mammadov E., ÖLMEZ Ö. F., yıldız Ö.
ACTA ONCOLOGICA TURCICA, vol.56, no.2, pp.153-160, 2023 (Peer-Reviewed Journal)
- VI. **The Optimal Treatment Approaches and Prognostic Factors in Elderly Patients with Advanced Stage Biliary Tract Tumors**
AYDIN S., BİLİCİ A., ÖLMEZ F. Ö., ÇAKAN B., YILMAZ C., AYDIN A., TOPÇU A., AYKAN M. B., KAHRAMAN S., ATÇI M. M., et al.
ACTA ONCOLOGICA TURCICA, vol.56, no.1, pp.81-89, 2023 (Peer-Reviewed Journal)
- VII. **SURVIVAL EFFECT OF PALLIATIVE RADIOTHERAPY IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER DEVELOPING OLIGO-PROGRESSION UNDER ANTIANDROGEN TREATMENT**
Aydın S., Kutlu Y., Muğlu H., Açıkğöz Ö., Aydın A., Bilici A., Ölmez Ö. F., Unal D., Karcı E., Yıldız Ö.
İstanbul Tıp Fakültesi Dergisi, vol.86, no.2, pp.117-122, 2023 (ESCI)
- VIII. **Treatment Management of Leptomeningeal and Brain Metastases as a First Recurrence Site in a Case with Germ Cell Testicular Tumor**
GÖKTAŞ AYDIN S., BİLİCİ A., ÇAKIR A., ÖLMEZ Ö. F., CİLA A., ÜNAL D.
Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi, vol.36, no.1, pp.77-80, 2022 (Peer-Reviewed Journal)
- IX. **The Impact of Hybrid Capture-Based Comprehensive Genomic Profiling on Treatment Strategies in Patients with Solid Tumors**
Dişel U., Köse F., BİLİCİ A., ÖZGÜROĞLU M., SAĞLAM S., ŞEKER M., AKSOY S., TEK İ., MANDEL N. M., DEMİR G., et al.
Journal of Oncological Science, vol.8, no.2, pp.87-93, 2022 (Scopus)
- X. **FACTORS PREDICTING RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED GASTRIC CANCER LOKAL İLERİ MİDE KANSERİNDE NEOADJUVAN KEMOTERAPİYE YANITI ÖNGÖREN FAKTÖRLER**
Yıldırım E., Bektaş S., GÖKTAŞ AYDIN S., ER A. M., YANIK İ., GÜMÜŞKAYA P. Ö., YILMAZ B. U., BİLİCİ A., ÖNCEL M.
İstanbul Tıp Fakültesi Dergisi, vol.85, no.1, pp.41-50, 2022 (Scopus)
- XI. **The Effect of Cognitive Functions After Chemotherapy on Activity Performance and Social Participation in Breast Cancer Patients Meme Kanserli Hastalarda Kemoterapi Sonrası Bilişsel Fonksiyonların Aktivite Performansı ve Aktivite Katılım Üzerine Olan Etkisi**
Akdemir G., Ünsal E., TARAKCI D., BİLİCİ A., Ölmez F. Ö., YILDIZ Ö.
Archives of Health Science and Research, vol.8, no.3, pp.189-195, 2021 (Scopus)
- XII. **Real-Life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients with Metastatic Non-Small Cell Lung Cancer**
AYDIN S. G., AÇIKGÖZ Ö., KUTLU Y., BİLİCİ A., HAMDARD J., ÖLMEZ Ö. F., YILDIZ Ö.
ACTA ONCOLOGICA TURCICA, vol.54, no.3, pp.281-290, 2021 (Peer-Reviewed Journal)

- XIII. **Prognostic Factors for Operated Gallbladder Cancer**
Oven Ustaalioglu B. B., BİLİCİ A., Seker M., KEFELİ U., Aydin D., Celik S., Demir T., Erkol B.
Journal of Gastrointestinal Cancer, vol.50, no.3, pp.451-457, 2019 (Scopus)
- XIV. **Brain Metastasis in a Patient with Malignant Melanoma: Melanotic Pattern**
ARICI DÜZ Ö., YILMAZ N. H., BİRDAY E., ERTAN AKAN G., BİLİCİ A.
Türk Nöroloji Dergisi, vol.23, no.2, pp.79-80, 2017 (Scopus)
- XV. **The clinicopathologic characteristics and prognostic factors of gastroesophageal junction tumors according to Siewert classification**
Ustaalioglu B. B. Ö., Tilki M., Sürmelioğlu A., BİLİCİ A., Gönen C., Ustaalioglu R., Balvan Ö., ALIUSTAOĞLU M.
Turkish Journal of Surgery, vol.33, no.1, pp.18-24, 2017 (Scopus)
- XVI. **Medication errors in chemotherapy preparation and administration: A survey conducted among oncology nurses in Turkey**
Ulas A., Silay K., Akinci S., Dede D. S., AKINCI M. B., ŞENDUR M. A. N., ÇUBUKÇU E., Coskun H. S., Degirmenci M., UTKAN G., et al.
Asian Pacific Journal of Cancer Prevention, vol.16, no.5, pp.1699-1705, 2015 (Scopus)

Refereed Congress / Symposium Publications in Proceedings

- I. **Are pretreatment inflammation-based prognostic scores useful in predicting the outcomes of patients with ALK-positive NSCLC?**
ÖLMEZ Ö. F., BİLİCİ A., GÜRSOY P., ÇUBUKÇU E., YILDIZ O., SAKİN A., KORKMAZ T., ÇAKAR B., MENEKŞE S., AÇIKGÖZ O., et al.
IASLC 2019 World Conference on Lung Cancer, Barcelona, Spain, 7 - 10 September 2019, vol.14, pp.551-552
- II. **Systemic inflammatory markers as a predictors of response to crizotinib in patients with ALK-positive non-small-cell lung cancer**
BİLİCİ A., ÖLMEZ Ö. F., GÜRSOY P., ÇUBUKÇU E., YILDIZ O., SAKİN A., KORKMAZ T., ÇİL İ., ÇAKAR B., MENEKŞE S., et al.
IASLC 2019 World Conference on Lung Cancer, Barcelona, Spain, 7 - 10 September 2019, vol.14, pp.664-665
- III. **Economic Burden of Gastric Cancer in Turkey**
BİLİCİ A., GÜMÜŞ M., MALHAN B. S., Öksüz E., ÇAKMAK ÖKSÜZOĞLU Ö. B., YALÇIN Ş.
ISPOR 20th Annual European Congress, 4 - 08 November 2017
- IV. **Prognostic significance of positive lymph node ratio in patients with pN3 gastric cancer who underwent curative gastrectomy**
BİLİCİ A., ŞEKER M., USTAALIOĞLU BALA B. Ö., ÖLMEZ Ö. F., YILDIZ Ö., ÇAKIR A., ÖZKÖK ÇAĞLAR H. B., ÖNCEL M.
ESMO 19th World Congress on Gastrointestinal Cancer, Barcelona, Spain, 28 June - 01 July 2017, vol.28, pp.35-36
- V. **Malign Melanomlu Olguda Beyin Metastazı: Melanotik Patern**
ARICI DÜZ Ö., HELVACI YILMAZ N., BİRDAY E., AKAN G., BİLİCİ A.
52. Ulusal Nöroloji Kongresi-Antalya, Turkey, 25 November - 01 December 2016